Amylyx Pharmaceuticals, Inc. (AMLX) stock
AMLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$29.86−1.94 (-6.10%)
Close on Nov 12, 2026Market cap $3.33BP/E –Yield –
Amylyx Pharmaceuticals enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Amylyx Pharmaceuticals's enterprise value was $3.29B on Nov 11, 2026, against $1.30B a year earlier. Over the last 5 years it ranged from -$256.37M to $3.51B, with a median of $981.99M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $3.29B | +235.1% |
| 2025 | Dec 31, 2025 | $981.99M | +3874.5% |
| 2024 | Dec 31, 2024 | $24.71M | -96.1% |
| 2023 | Dec 29, 2023 | $638.63M | -68.1% |
| 2022 | Dec 30, 2022 | $2.00B | – |
See a number that looks wrong?